Strameno Ltd., Salisbury, Wiltshire, United Kingdom and AlgiSys Biosciences Inc. Cleveland, Ohio, USA today announced that they have entered a Memorandum of Understanding.
Strameno and AlgiSys are both working at the cutting edge of algae technologies, which can have significant impacts on human and animal health while addressing the catastrophic problem of overfishing. The partnership will enable both companies to leverage their complementary expertise and knowledge by creating new products to supply an ever-expanding market for omega-3s, antioxidants, and plant protein.
Dr. Lydia Brown, Strameno Director, noted: “We’re excited to be working with AlgiSys. Our expertise in DHA and niche algae strains combined with AlgiSys expertise in algae commercialization and fermentation technology will help us scale and reach an increasingly wider audience of consumers interested in the many nutritional and health benefits of algal ingredients and products.”
Dr. Charles Roe, AlgiSys CTO, added: “Strameno’s deep knowledge and expertise in microalgae and DHA is unparalleled. Their ultra-high DHA strain of microalgae is a perfect complement to our fermentable strains of microalgae containing EPA omega-3. Working with their team will allow us to expand beyond EPA into carotenoids and DHA for all our targeted vertical markets.”